Recent understanding of the molecular background of melanoma development and progression has resulted in promising novel therapies targeting mutant B-Raf enzyme, or the CTLA-4- or PD-1-immune checkpoints in advanced, unresectable cases [1]. Here, CTLA4 is linked to melanoma.